See the published version of this preprint at Scientific Reports.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Shai Efrati
Shamir Medical Center
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Most patients infected with SARS-CoV-19 are asymptomatic or mildly symptomatic. However, the early and late antibody kinetics in those patients have not yet been fully defined. Confirmed SARS-CoV-2 patients, and their household contacts were evaluated over a period four months. The evaluation procedure included symptom monitoring, viral load and serology analysis every ten days. A total of 1334 serum samples were collected from 135 patients and analyzed using three assays for IgG-N, IgG-S and IgM antibodies. Of the study participants, 97% were seropositive during the study and two distinct clusters were identified. These clusters were significantly different in their inflammatory related symptoms. Peak IgG-S was 45.8 AU/ml for cluster 1 and 71.5 AU/ml for cluster 2 (P = 0.004), whereas IgG-N peaks were 4.5 and 5.8 (P = 0.001) respectively. Finally, a decision tree model was designed to predict the disease phase based on the serological titer levels, and had an overall accuracy of 80.7%. The specific profile of seroconversion and decay of serum antibodies can be used to predict the time course from the acute infection.
Keywords
COVID-19, SARS-CoV-2, immunology, epidemiology
Figure 1
Figure 2
Figure 3
Figure 4
No competing interests reported.
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Scientific Reports.
Version 1
Posted 26 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 30 Apr, 2021
Reviews received
Received 16 Apr, 2021
Reviewers agreed
On 12 Apr, 2021
Reviewers invited
Invitations sent on 31 Mar, 2021
Editor assigned
On 31 Mar, 2021
Editor invited
On 30 Mar, 2021
Submission checks complete
On 25 Mar, 2021
First submitted
On 11 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
See the published version of this preprint at Scientific Reports.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Shai Efrati
Shamir Medical Center
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Scientific Reports.
Version 1
Posted 26 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 30 Apr, 2021
Reviews received
Received 16 Apr, 2021
Reviewers agreed
On 12 Apr, 2021
Reviewers invited
Invitations sent on 31 Mar, 2021
Editor assigned
On 31 Mar, 2021
Editor invited
On 30 Mar, 2021
Submission checks complete
On 25 Mar, 2021
First submitted
On 11 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Scientific Reports.
Most patients infected with SARS-CoV-19 are asymptomatic or mildly symptomatic. However, the early and late antibody kinetics in those patients have not yet been fully defined. Confirmed SARS-CoV-2 patients, and their household contacts were evaluated over a period four months. The evaluation procedure included symptom monitoring, viral load and serology analysis every ten days. A total of 1334 serum samples were collected from 135 patients and analyzed using three assays for IgG-N, IgG-S and IgM antibodies. Of the study participants, 97% were seropositive during the study and two distinct clusters were identified. These clusters were significantly different in their inflammatory related symptoms. Peak IgG-S was 45.8 AU/ml for cluster 1 and 71.5 AU/ml for cluster 2 (P = 0.004), whereas IgG-N peaks were 4.5 and 5.8 (P = 0.001) respectively. Finally, a decision tree model was designed to predict the disease phase based on the serological titer levels, and had an overall accuracy of 80.7%. The specific profile of seroconversion and decay of serum antibodies can be used to predict the time course from the acute infection.
Figure 1
Figure 2
Figure 3
Figure 4
No competing interests reported.
This is a list of supplementary files associated with this preprint. Click to download.
Loading...